Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes : Episode 8

Patient Selection for Teplizumab and Infusion Process

January 20, 2025

By Javier Morales, MD, FACP, FACE
David Robertson, MD

Opinion

Video

Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.

EP: 1.Assessing the Burden of Type 1 Diabetes

EP: 2.Guidelines for Type 1 Diabetes Screening

EP: 3.Defining the Stages of Type 1 Diabetes

EP: 4.Impact of Delayed Intervention In Stage 2 Type 1 Diabetes

EP: 5.Screening for Autoantibodies in Type 1 Diabetes

EP: 6.Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1

EP: 7.Clinical Trial Data for Teplizumab

Now Viewing

EP: 8.Patient Selection for Teplizumab and Infusion Process

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!